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Edited by Lukas HuberAbstract Ets-1 is a cellular homologue of the product of the
viral ets oncogene of the E26 virus, and it functions as a tissue-
speciﬁc transcription factor. It plays an important role in cell
proliferation, diﬀerentiation, lymphoid cell development, trans-
formation, angiogenesis, and apoptosis. Ets-1 controls the
expression of critical genes involved in these processes by binding
to ets binding sites present in the transcriptional regulatory re-
gions. Here, we transiently overexpressed Ets-1 in MCF-7 and
comprehensively searched for potential downstream targets of
Ets-1 by cDNA microarray analysis. The expressions of several
interferon-related genes including STAT1 and Nmi were aug-
mented by the overexpression of Ets-1. RT-PCR and Western
blotting conﬁrmed the increase in the levels of STAT1 and
Nmi mRNA and protein. In contrast, Ets-1 siRNA decreased
the expression of STAT1 and Nmi proteins. As in our transient
transfection experiments, stable overexpression of Ets-1, also in-
creased the protein expression of STAT1 and Nmi in MCF-7
cells. Taken together, our results indicate that STAT1 and
Nmi are downstream targets of Ets-1 in MCF-7 human breast
cancer cells.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The Ets-1 protein is a member of the Ets family of transcrip-
tion factors that share a unique DNA binding domain, the Ets
domain [1]. The DNA binding domain allows these proteins to
speciﬁcally bind to promoter elements that contain a GGAA/T
motif, and it has been a challenge to diﬀerentiate redundant
from speciﬁc functions of various Ets proteins in vivo. How-
ever, it has been suggested that such functional redundancy
may be a central component of a network of diﬀerentially reg-
ulated speciﬁc Ets factors, resulting in distinct biological and
pathological consequences [2]. The Ets proteins transcription-
ally regulate a number of genes involved in cellular prolifera-*Corresponding author. Fax: +82 2 3410 0041.
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doi:10.1016/j.febslet.2005.06.011tion, diﬀerentiation, development, hematopoiesis, apoptosis,
metastasis, tissue remodeling, angiogenesis and malignant
transformation of cell. The Ets transcription factors have been
implicated in tumorigenesis both through formation of gain-
of-function oncoproteins in acute leukemia and Ewing sarcoma
and through overexpression in tumors of epithelial origin,
including breast cancer [3,4]. Fusion proteins formed between
the pointed domain of the Ets transcriptional repressor TEL
and certain kinases or between TEL and the transcription factor
AML-1 are known to be responsible for the development of
leukemia by rendering constitutively active kinases [5,6]. In
Ewings tumor, the Ets domain of Fli-1, Erg-1, ETV-1, E1AF
or FEV is fused to the Ewing sarcoma protein generating a
transforming transcription factor that deregulates transcription
[7].
Upregulation of expression of the Ets-1 gene, a prototype ets
gene, has been documented in many types of human cancers,
including epithelial ovarian tumors and breast cancer [8–11].
The degree of Ets-1 expression was correlated to the extent
of breast carcinoma invasion and the atypism of carcinoma
was signiﬁcantly correlated with Ets-1 expression [10]. Ets-1
has been reported as an independent prognostic marker for
breast relapse-free survival in breast cancer, which was not
linked to other tumor markers, such as nodal status, tumor
size, histological grade or estrogen receptor status [9]. In addi-
tion, the role of Ets-1 protein in breast cancer metastasis has
been implicated by ﬁnding high Ets-1 protein levels in breast
cancer tissues compared to the ﬁbroadenoma specimens and
by the correlation with urokinase plasminogen activator
(uPA), a matrix-degrading protease [11]. The Ets factors Ets-
1, Ets2, Fli1, and Erg transform cells when overexpressed, an
eﬀect that is associated with the stimulation of cell prolifera-
tion [12–15]. Few other functional roles of Ets-1 in tumorigen-
esis have also been postulated. Ets-1 regulates the expression
of genes encoding for enzymes involved in degradation of
the extracellular matrix, such as MMP-1, MMP-3, MMP-7,
and MMP-9 [16]. It has been demonstrated that the expression
of Ets-1 lacking its activation domain decreased uPA proteo-
lytic activity and cell motility and impaired normal tubulogen-
esis and cancerous scattering in mammary epithelial cells [17].
These ﬁndings imply that Ets-1 is required for mammary onco-
genesis by regulating the expression of target genes whose
products play critical roles in breast cancer, although an arrayblished by Elsevier B.V. All rights reserved.
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undeﬁned.
Over 200 ets target genes were identiﬁed and an array of
genes has been shown to be regulated via ets binding sites
[16]. The identiﬁcation of downstream cellular target genes
of ets proteins is essential. The objective of the present study
was to identify potential downstream target genes of Ets-1 in
MCF 7 breast cancer line in order to further clarify its role
and mechanism in mammary tumorigenesis. We transiently
overexpressed Ets-1 gene in Ets-1 deﬁcient MCF-7 breast can-
cer cell and comprehensively searched for potential down-
stream targets by cDNA microarray analysis. Transiently
transfected Ets-1 in MCF-7 breast cancer cell line induced
interferon-related genes including STAT1 and Nmi, which
were conﬁrmed in stably ets-1 transfected MCF-7 cell. Results
suggest that STAT1 (signal transducers and activators of tran-
scription) and Nmi (N-Myc-interacting protein) are down-
stream targets of Ets-1 in breast cancer.2. Materials and methods
2.1. Cell lines
MCF-7 and MDA-MB-231 cell lines were purchased from the
American Type Culture Collection (Manassas, VA) and cultured and
maintained in RPMI 1640 medium (BioWhittaker, Walkersville,
MD) supplemented with 10% fetal bovine serum, penicillin, and strep-
tomycin at 37 C in 5% CO2.
2.2. Transient and stable transfection of Ets-1 into MCF-7 cells
An expression vector for FLAG-tagged Ets-1 was constructed by
subcloning PCR-ampliﬁed cDNA into the G418-resistant plasmid
pcDNA3.1 vector. MCF-7 cells were transiently transfected using
Eﬀectene transfection reagent (QIAGEN Inc., Valencia, CA) accord-
ing to the manufactures instructions. MCF-7 cells were stably trans-
fected with either vector (pcDNA3.1-Ets-1) or pcDNA3.1 in the
presence of Eﬀectene transfection reagent (QIAGEN Inc.) for 48 h
and treated with 500 lg/ml of G418, and G418-resistant colonies were
selected for two months.
2.3. RT-PCR analysis
Total cellular RNA was isolated by using Trizole (Gibco BRL,
Carlsbad, CA) according to the manufacturers instruction. For re-
verse transcription (RT)-PCR, 2 lg of RNA was treated with
RNase-free DNase, and cDNA was obtained using Moloney murine
leukemia virus reverse transcriptase. cDNA (1 ll) was ampliﬁed by
PCR (denaturation for 1 m at 94 C, annealing for 1 m at 58 C, and
elongation for 1 m at 72 C) using Ets-1 (28 cycles), STAT1 (30 cycles),
Nmi (30 cycles) or b-actin primers (25 cycles). The primers used in this
analysis are as follows: b-actin, 5 0-atc tgg cac cac acc ttc tac aat gag ctg
ctg cg-3 0 and 5 0-cgt cat act cct gct tgc tga tcc aca tct g-3 0; Ets-1, 5 0-aaa
cag caa agaaat gat gt-3 0 and 5 0-gct cga gaa agc agtctt ta-3 0; STAT1, 5 0-
gat act tta gct tta att tta aaa caa aac-3 0 and 5 0-gtt att agg gtg gta ttt agt
cta tta-3 0; Nmi, 5 0-ata aac aaa act ttt tat tac agt gca ctt-3 0 and 5 0-gca
gtg ctt ctg aca gga gt-3 0. The reaction products were visualized by sub-
jecting them to electrophoresis in 1.5% agarose in 1· TBE buﬀer con-
taining 0.5 lg/ml ethidium bromide. The ﬁnal normalized results were
calculated by dividing the relative transcript levels of the test genes by
the relative amounts of b-actin transcripts.2.4. Western blot analysis and antibodies
Total cell extracts were obtained using ice-cold RIPA buﬀer (0.5%
sodium deoxycholate, 1% Nonidet P-40, 150 mM NaCl, 50 mM Tris,
pH 7.5, 0.1% SDS, and 1 mM PMSF). After 20-min incubation of
the cell extracts on ice, they were centrifuged for 20 min at 12000 · g
at 4 lg and the supernatant collected. Proteins were quantiﬁed with
the BCA protein assay kit (Pierce, Rockford, IL, USA). Lysates con-
taining equal amount of total protein were separated by SDS–PAGE
under reducing conditions and transferred to nitrocellulose membrane.The membrane was incubated for 2 h in blocking solution containing
5% non-fat dry milk to inhibit non-speciﬁc binding. The membrane
was incubated with the primary antibody for 2 h. After several washes
in PBS, the membrane was incubated with 1:3000 HRP-conjugated
secondary antibodies (Zymed). The blots were developed using the
ECL chemiluminescent kit (Amersham, Arlington Heights, IL). Anti-
Ets-1 (dilution factor 1:1000), STAT1 (Stat1 alpha p91 (C-111),
1:1000), phospho-STAT1 (1:1000) and Nmi (1:1000) antibodies were
used, which were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Anti-b-actin FLAG was purchased from Sigma (St. Louis,
MO).
2.5. cDNA microarray analysis
The cDNA microarray containing a set of 17448 sequence-veriﬁed
human cDNA clone was provided by GenomicTree Inc. (Korea).
The synthesis of target cDNA probes and hybridization were per-
formed as previously described [18]. Each 100 lg total RNA was re-
verse transcribed in the presence of Cy3 or Cy5-dUTP (NEN Life
Sciences, Boston, MA) at 42 C for 2 h. The control RNA was labeled
with ﬂuorescent Cy3-dUTP and the testing RNA was labeled with
ﬂuorescent Cy5-dUTP. Both the Cy3 and Cy5-labeled cDNAs were
puriﬁed using PCR puriﬁcation kit (QIAGEN Inc.) as recommended
by the manufacturer. The puriﬁed cDNA was resuspended in 80 ll
of hybridization solution containing 3.5· SSC, 0.3% SDS, 20 lg of hu-
man Cot-1 DNA, 20 lg of poly A RNA and 20 lg of the yeast tRNA
(Invitrogen, Carlsbad, CA). The hybridization mixtures were heated at
100 C for 2–3 min and directly pipetted onto microarrays. The arrays
hybridized at 65 C for 12–16 h in the humidiﬁed hybridization cham-
ber (GenomicTree Inc.). The hybridized microarrays were washed with
2· SSC for 2 min, 0.1· SSC/0.1% SDS for 5 min, and 0.1· SSC for
5 min. The washed microarrays were immediately dried using
the microarray centrifuge (GenomicTree Inc.). All microarray hybrid-
izations were performed in duplicates and we collected the average
data.
2.6. Data acquisition and analysis
The hybridization images were analyzed by GenePix Pro 4.0 (Axon
Instruments, CA). The average ﬂuorescence intensity for each spot was
calculated and local background was subtracted. All data normali-
zation and statistical analysis were performed using GeneSpring 6.1
(Silicon Genetics, USA). Genes were ﬁltered according to the two-
component model for estimating variation from control strength
[19]. Intensity-dependent normalization (Lowess) was performed,
where the ratio was reduced to the residual of the Lowess ﬁt of the
intensity vs. ratio curve. The averages of normalized ratios were calcu-
lated by dividing the average of normalized signal channel intensity by
the average of normalized control channel intensity. Hierarchical clus-
tering was performed by similarity measurements based on Pearson
correlations around 0. Functional annotation of genes was performed
according to Gene Ontologye Consortium (http://www.geneontology.
org/index.shtml) by GeneSpring 6.1.2.7. siRNA synthesis
Small interfering RNA (siRNA) were synthesized and high-perfor-
mance puriﬁed (Qiagen-Xeragon, Germantown, MD). The sequence





and its corresponding complementary strand
5 0r(GAACUCCAAACAGCACACC)d(TT)3
0
. siRNAs were dissolved
in buﬀer (100 mM potassium acetate, 30 mM HEPES–potassium
hydroxide, and 2 mMmagnesium acetate, pH 7.4) to a ﬁnal concentra-
tion of 20 lM. The siRNA solutions were heated to 90 C for 60 s and
incubated at 37 C for 60 min prior to use to disrupt any higher order
aggregates formed during synthesis.2.8. Small interfering RNA
The 2 · 105 cells were plated into 35 mm 6-well plate and allowed to
adhere for 24 h. Eight microliters of RNAiFect transfection reagent
(QIAGEN Inc.) and two microliters of siRNA solution per well was
added to Buﬀer EC-R for a ﬁnal complexing volume of 100 ll. This
complex was gently mixed and incubated at room temperature for
20 min. The transfection agent/siRNA complex was added into the
wells containing 1900 ll DMEM with 10% FBS and incubated in nor-
mal cell culture conditions.
Table 1
List of augmented genes in cDNA microarray analysis
Type of gene Fold
induction
IFN-induced transmembrane protein 2 (1-8D) 6.973
Nmi 12.6
IFN-a inducible protein (clone IFI-15K) 29.32
IFN-a inducible protein (clone IFI-6-16) 18.364
IFN-induced transmembrane protein 2 (1-8D) 10.003
IFN-stimulated gene 20 kDa 8.90
IFN-stimulated transcription factor 3, gamma 48 kDa 8.652
STAT1 5.17
B-factor, properdin 4.631
Nerve growth factor receptor
(TNFR superfamily, member 16)
4.25
Major histocompatibility complex, class I, C 4.25
Nuclear transport factor 2 3.02
Bone marrow stromal cell antigen 2 16.18
Leucine aminopeptidase 3 6.191
Lectin, galactoside-binding, soluble, 3 binding protein 15.807
Cullin 5 8.61
Apolipoprotein L, 3 10.49
Adrenergic, alpha-1D-, receptor 5.312
Myeloid diﬀerentiation primary response gene 3.232
Metallothionein 1B 2.94
Proteasome (prosome, macropain) subunit, beta type 4.897
Major histocompatibility complex, class I, A 4.13
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3.1. cDNA microarray results in ets-1 transiently transfected
MCF-7 cell line
To identify genes transcriptionally regulated by Ets-1 in
breast cancer cells, we transfected MCF-7 cell line with Ets-1
and compared the expression proﬁle with that of MCF-7 in-
fected with G418-resistant plasmid pcDNA3.1 vector. In order
to minimize the interaction with endogenous Ets-1, MCF-7,
MDA-MB-231, SKBR-3 breast cancer cell lines were pre-
screened for the level of endogenous Ets-1 expression and
found that MCF-7 cell line expressed less than 10% compared
to other cell lines (data not shown). After 24 h incubation, we
analyzed the expression proﬁle with a cDNA microarray.
Among the 17448 human genes in the microarray, 286 of them
were augmented in their expression more than 2-fold and 42 of
them were augmented in t test. Of the 42 augmented genes in
cDNA microarray analysis, relevant genes are listed in Table
1. In particular, genes coding for proteins involved in inter-
feron (IFN) signaling pathway, such as IFN-a inducible pro-
tein (clone IFI-15K, IFI-6-16), IFN-induced transmembrane
protein 2 (1-8D), IFN-c induced protein, IFN-stimulated gene
20 kDa, IFN-stimulated transcription factor 3, gamma
48 kDa, STAT1 and Nmi were markedly augmented in their
expression level.
Of these proteins, we were interested in STAT1 and Nmi in
relation to Ets-1 overexpression in breast cancer cells. STAT1,
a member of the STAT family, plays an essential role in regu-
lating the growth, diﬀerentiation, death of normal and tumor
cells in response to various stimuli, including cytokines and
growth factors [20]. Nmi has been shown to augment STAT-
mediated transcription in response to IL-2 and IFN-c [21].
Because there were signiﬁcantly augmented expressions of
IFN-related protein after transfection with Ets-1 construct,
we investigated the transcriptional regulation of STAT1 and
Nmi by Ets-1. As shown in Fig. 1A, transient overexpressionof Ets-1 gene led to an enhancement of STAT1 and Nmi
mRNA expression levels. A time course experiment revealed
that an increase in the level of STAT1 and Nmi proteins were
evident as early as 24 h after the Ets-1 transfection and contin-
ued to increase until 48 h after transfection (Fig. 1B). The in-
crease in expression level of phospho-STAT1 was observed
at 24 h after the Ets-1 transfection by Western analysis
(Fig. 1C).
3.2. Ets-1 enhances STAT1 and Nmi expression in a stable
MCF-7 cell line
In order to investigate the eﬀect of an intracellular accumu-
lation of Ets-1, we established a stable MCF-7 cell line trans-
fected with either Ets-1 or a vector. Nine G418-resistant
clones were isolated and screened for expression of Ets-1 by
RT-PCR and Western blot analysis. As shown in Fig. 2, clone
#10 and #14 stably expressed Ets-1 protein and showed in-
creased expression of STAT1 and Nmi, whereas clone #1
(without Ets-1 expression) did not show STAT1 or Nmi
expression in Western blot or RT-PCR analysis. These data
demonstrated that the overexpression of Ets-1 has led to an
enhancement of intracellular STAT1 and Nmi expression.
3.3. STAT1 and Nmi induction are blocked by Ets-1 siRNA in
MCF-7 cell
siRNA to Ets-1 provide further evidence for the positive
regulatory role of Ets-1 in the regulation of STAT1 and Nmi
(Fig. 3). The ability of Ets-1 siRNA to suppress Ets-1 expres-
sion was conﬁrmed by Western blot analysis. Up to 50% sup-
pression of Ets-1 protein expression was observed within 24 h
of transfection. Actin expression was unaﬀected by either con-
trol or Ets-1 siRNA treatment, indicating that non-speciﬁc
downregulation of protein expression did not occur (data not
shown). Next, we determined the eﬀect of Ets-1 siRNA on
STAT1 and Nmi expression in MDA-MB-231, which ex-
presses endogenous Ets-1 in higher level than MCF-7. STAT1
and Nmi were both downregulated by the addition of Ets-1
siRNA in MDA-MB-231 cell line.4. Discussion
Recently, the association of Ets-1 with invasiveness and
metastasis has been implicated in breast cancer cells. The de-
tailed mechanism of how Ets-1 modulate the downstream gene
transcription during tumorigenesis remains uncertain. The
goal of this study was to identify downstream cellular targets
that are either directly or indirectly regulated by the Ets-1 proto-
oncogene. The cDNA microarray analysis revealed that Ets-1
augmented the expression of 9 IFN-related genes in breast can-
cer cells. None of these genes have been previously recognized
as putative targets of Ets-1 in breast cancer. We further clari-
ﬁed two of these genes, STAT1 and Nmi.
STAT protein usually exists in the cytoplasm as a monomer
in unstimulated cells and forms a dimer upon activation by
tyrosine phosphorylation in response to ligand stimulation.
The STAT dimer then translocates into the nucleus to activate
transcription of various genes. Initially identiﬁed as playing a
key role in hematologic and immune cells, STATs are increas-
ingly recognized as an important factor in a wide array of hu-
man cancers. A number of proteins have been identiﬁed to
Fig. 1. Eﬀect of exogenous Ets-1 on the expression of STAT and Nmi. Characterization of MCF-7 cells transiently transfected with an Ets-1
expression plasmid. (A) MCF-7 cells were transfected with Ets-1-FLAG construct and total RNA was extracted from the cells. STAT1 and Nmi
mRNA level was assessed by RT-PCR. The RNA amount was quantiﬁed by densitometric analysis, and the ratio of STAT, Nmi/b-actin in each lane
was calculated. (B) MCF-7 cells were transfected with Ets-1-FLAG construct and were harvested at the indicated time. Ets-1, FLAG, STAT1 and
Nmi protein level were assessed by Western blot. The protein amount was quantiﬁed by densitometric analysis, and the ratio of STAT, Nmi/b-actin
in each lane was calculated.
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various steps of the activation–inactivation cycle [22]. Acti-
vated STAT1, in particular, has been found in nuclear extracts
from breast cancer specimens [23]. The role of STAT1 activa-
tion is not clear in mammary tumorigenesis, however. Breast
cancer patients with high STAT1 activation were reported to
have a longer overall and relapse-free survival, although the
STAT1 activation and expression of the STAT1 protein were
not linked [24]. Few studies have suggested a direct binding
of Ets-1 and STAT proteins. Travagli et al has demonstrated
that Ets-1 physically interacts with STAT6, which is implicated
in the regulation of Socs-1 expression in human keratinocytes
[25]. The involvement of STAT1 and Ets elements such as
PU.1 and Spi-B in interferon-c induction of CD40 transcrip-
tion in macrophages has recently been proposed [26]. The cel-lular implication of the physical binding between STAT1 and
Ets-1 in breast cancer cells needs to be deﬁned.
Nmi was originally identiﬁed as a binding partner to the
Myc family proteins Max and Mxi [27]. Nmi lacks an intrinsic
transcriptional activation domain, but augments transcription
in both Il-2-IFN-a-mediated signaling by acting as an adaptor.
In a yeast two-hybrid screen using the coiled-coil region of
STAT5b as the bait, Nmi was identiﬁed as a STAT5-interact-
ing protein [28]. In this study, Nmi has been suggested
as a potentiator of transcription that enhances the recruitment
of coactivators to STATs in response to interleukin-2 and
IFN-c. Interestingly, they found that Nmi also interacted
with all STAT proteins except STAT2. In this study, we found
that the expressions of Nmi protein and mRNA were elevated
in Ets-1 transfected cells. Although the exact mechanism
Fig. 2. Eﬀect of endogenous Ets-1 on the expression of STAT and Nmi. Characterization of MCF-7 cells stably transfected with an Ets-1 expression
plasmid. (A) Ets-1, FLAG, STAT and Nmi protein levels determined by Western blot in control and Ets-1-FLAG transfected MCF-7 clones. (B) Ets-
1, STAT and Nmi RNA levels determined by RT-PCR in control and Ets-1-FLAG transfected MCF-7 clones. Lane 1, parental cell; lane 2, MCF-7
cells only transfected with the plasmid that confers resistance to G418; lanes 3–4, Ets-1-FLAG transfected clones #1, #2; lanes 5–6, cells transfected
with the same plasmid as lane 2 but containing also the Ets-1-FLAG construct.
Fig. 3. The downregulation of STAT1 by Ets-1 siRNA. Representative Western blot for Ets-1 and STAT1 following treatment with Ets-1 siRNA.
Ets-1 and STAT1 expressions were suppressed by Ets-1-speciﬁc siRNA. b-Actin expression was unaﬀected by siRNA treatment.
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can be speculated that Nmi may interact with STAT1, which is
upregulated by Ets-1.
Taken together, cDNA gene expression proﬁling analysis
demonstrated that STAT1 and Nmi are downstream cellular
targets of Ets-1 in breast cancer cells. These proteins may be
postulated to be potential targets to control tumor-associated
Ets-1 activity in breast cancer patients.
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